CME in Minutes: Education in Primary Care

Please visit answersincme.com/UJD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in transgender medicine discusses improving approaches to guideline-concordant cervical cancer screening by healthcare professionals in patients who are transgender men or nonbinary. Upon completion of this activity, participants should be better able to: Recognize the clinical impact of low uptake of cervical cancer screening among transgender men (TM) and people who identify as nonbinary (NB); Review key concerns experienced by TM and NB people that result in lower rates of cervical cancer screening; and Identify tailored strategies to enhance acceptance of cervical cancer screening in TM and people who identify as NB.

Please visit answersincme.com/EXA860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma. Upon completion of this activity, participants should be better able to: Outline guideline-recommended approaches to the first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) using PD-1 inhibitors; Review the latest clinical data for first-line PD-1 inhibitor–based therapies in the treatment of patients with R/M HNSCC; and Describe clinical strategies to optimize management of patients with R/M HNSCC treated with PD-1 inhibitors.

Please visit answersincme.com/TJX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cardiology discusses low-density lipoprotein (LDL) receptor–independent therapies for homozygous familial hypercholesterolemia (HoFH) via two patient case studies. Upon completion of this activity, participants should be better able to: Identify patients with HoFH through differential diagnosis; Review the clinical profiles of novel strategies to reduce LDL cholesterol in patients with HoFH that work independently of LDL receptors; and Outline patient-centered strategies to maximize quality of life for patients with HoFH on lipid-lowering therapies.

Please visit answersincme.com/SRG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in dermatology discuss the diagnosis and treatment of prurigo nodularis. Upon completion of this activity, participants should be better able to: Recognize the need for treatment intensification in patients with prurigo nodularis (PN), including patients of color, using novel biologic therapies; Review the clinical profiles of novel biologic therapies for PN; and Outline clinical factors that may facilitate the optimal use of biologic therapies in patients with PN.

Please visit answersincme.com/YSM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in ophthalmology discuss timely diagnosis of diabetic macular edema (DME) and treatment with anti–vascular endothelial growth factor (VEGF) agents. Upon completion of this activity, participants should be better able to: Recognize best practices to achieve a prompt and accurate diagnosis of DME; Describe guideline-concordant, evidence-based strategies to select appropriate therapy for patients with DME; and Review the clinical profiles of longer-acting VEGF-targeted agents with phase 3 trial evidence in the treatment of DME.

Please visit answersincme.com/EKH860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses frontline immunotherapy-based combination strategies to improve outcomes in patients with advanced biliary tract cancer. Upon completion of this activity, participants should be better able to: Review the rationale for including immunotherapy as a component of a therapeutic approach for patients with advanced biliary tract cancer (BTC); Describe the clinical profiles of immunotherapy plus chemotherapy combinatorial approaches for the treatment of advanced BTC; and Outline practical strategies to enhance evidence-based care of patients with advanced BTC on a combined immunotherapy plus chemotherapy approach.

Please visit answersincme.com/XTX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, two experts in cardiology discuss the diagnosis and management of homozygous familial hypercholesterolemia (HoFH). Upon completion of this activity, participants should be better able to: Describe the clinical impact of early and intensive treatment for patients with HoFH; Identify patients with HoFH through differential diagnosis; and Review the clinical profiles of novel strategies to reduce low-density lipoprotein (LDL).

Please visit answersincme.com/GQB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in hematology-oncology discuss B-cell maturation antigen (BCMA)–targeted therapies in the treatment of relapsed/refractory multiple myeloma. Upon completion of this activity, participants should be better able to: Identify where BCMA-targeted therapies fit into the current treatment paradigm of RRMM; Describe the clinical profiles of new and emerging BCMA-targeted bispecific antibodies in heavily treated RRMM; and Outline strategies to optimally incorporate novel BCMA-targeted bispecific antibodies into the treatment paradigm of RRMM.

Please visit answersincme.com/CAC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in melanoma discusses the use of neoadjuvant-adjuvant immunotherapy to improve outcomes in patients with resectable melanoma. Upon completion of this activity, participants should be better able to: Review the rationale for the use of neoadjuvant-adjuvant immunotherapy for patients with resectable melanoma; Describe the clinical profiles of the emerging neoadjuvant-adjuvant immunotherapeutic regimens in patients with resectable melanoma; and Identify patients for whom a neoadjuvant-adjuvant approach may be appropriate based on available clinical evidence.

Please visit answersincme.com/ZRV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, two experts in lung carcinoma discuss the latest data in first-line chemoimmunotherapy for non–small-cell lung cancer.Upon completion of this activity, participants should be better able to: Outline which patients might align with first-line chemoimmunotherapy regimens for advanced NSCLC; Review the clinical profiles of chemoimmunotherapy regimens in the first-line setting for the treatment of advanced NSCLC; and Translate the latest data informing the use of first-line chemoimmunotherapy regimens to individualized care of patients with advanced NSCLC.